NCT00147745View on ClinicalTrials.gov

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

Colesevelam

Colesevelam 3.8g for 12 weeks

DRUG

Colesevelam matching placebo

Colesevelam matching placebo for 12 weeks

DRUG

Insulin glargine (Lantus)

Insulin glargine for 12 weeks

Trial Locations (1)

92161

San Diego VMC, San Diego

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY